Wortmannin

For research use only.

Catalog No.S2758 Synonyms: KY 12420

164 publications

Wortmannin Chemical Structure

CAS No. 19545-26-7

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock
USD 747 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Wortmannin has been cited by 164 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NH3MSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[yMlUh|ryP Ml[yNU01KGR? MknaSG1UVw>? MmfS[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> NI\Fd3kzPTR7MEO4Ny=>
H1703 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHqNk42KM7:TR?= Mm\JNU01KGR? MX;EUXNQ M1rrTIVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv Mn6zNlU1QTB|OEO=
HUVECs MoftR5l1d3SxeHnjbZR6KEG|c3H5 NWLDXFFsOTByIH7N M3vCWFI1KGh? MlK3ZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MkTrNlU1PTBzOE[=
APRE-19 NVTjeld2SXCxcITvd4l{KEG|c3H5 NEW4dFE2KM7:TR?= M3v1NlI1KGh? MlX6ZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? NXrrfpZvOjV|Mkm2NVc>
MDA-MB-231 NYjteJFoSXCxcITvd4l{KEG|c3H5 NHHYNlMyyqEQvF5CpC=> MYq0PEBp NYnpTJdiTE2VTx?= MmXI[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJJRz\WG2ZXSge4l1cCB{NTFOwG0hd2ZiRkGgc5IhTjJiwrC= M3e0elI2OzByOUOy
MCF7 M{K3PGZ2dmO2aX;uJGF{e2G7 NFPTXWIyODBibl2= NFzaUVIzPCCq M4\Xb4VtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 MVOyOVE4OjV3Nx?=
HT-29  NY\CV5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxMlXDqML3TR?= M4i3Rlk3KGh? M3fJdoRm[3KnYYPld{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgbY5pcWKrdHXkJIJ6KEu\TlG= Mlu1NlUxOTJzMkO=
MO59K  MmTDR5l1d3SxeHnjbZR6KEG|c3H5 NWTlS4pYPcLizszN NV;vVpBqPyCm MnrlSG1UVw>? M1\IZoVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M{PkNFI1QTV|NU[x
MO59J MmrOR5l1d3SxeHnjbZR6KEG|c3H5 M{LyW|XDqM7:TR?= NW\5SYVGPyCm MkG0SG1UVw>? M{jDbIVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= Mn;nNlQ6PTN3NkG=
MO59K  MmP4RZBweHSxc3nzJGF{e2G7 NXPKd5ZXOTBizszN MVmyOEBp NVXBb4VRTE2VTx?= M1vXZYlv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NWThNZJEOjR7NUO1OlE>
MO59J M161VWFxd3C2b4Ppd{BCe3OjeR?= NFrBbnUyOCEQvF2= NV;0cHBtOjRiaB?= M2XvWmROW09? M3;TU4lv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? MoHvNlQ6PTN3NkG=
HepG2 NFPmbWJHfW6ldHnvckBCe3OjeR?= M3fsc|ExOCCwTR?= NF65XoUxNjViaB?= MkGxSG1UVw>? MkTzZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NHnyNVMzPDh4M{O1NC=>
A549  MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkTVM{KML3TdMg NVnMcJlTOiCq MnHnd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MYGyOFg1Pzh4Mx?=
A549  MlnRSpVv[3Srb36gRZN{[Xl? NWfTe5RFOTEEoN88ceKh M4jkT|E3KGh? NFT0WZVFVVOR MmTjcY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu NFzMdmgzPDhyMkGxNS=>
SK-N-LO NXe0TZBLTnWwY4Tpc44hSXO|YYm= M4\Le|ExOCCwTR?= MWqwMlUhcA>? MYrk[YNz\WG|ZYOgeIhmKHO2aX31cIFvfCCnZn\lZ5R{KG:oIH3vdpBpcW6nIH;uJGFsfCCyaH;zdIhwenmuYYTpc44> NFvuPWozPDZ3NE[wOi=>
HL-60 MUXGeY5kfGmxbjDBd5NigQ>? NGDGT5oxNjIEoN88US=> MWi3NkBp M1fIVYJtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> MWCyOFYxPzJ5Mx?=
HepG2  MU\GeY5kfGmxbjDBd5NigQ>? MV:yNFAhdk1? NIPtZlAxNjViaB?= NVfPdGN{[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= MkHmNlQ2OzVzOUK=
H520 MYPGeY5kfGmxbjDBd5NigQ>? MlnVNVDDqM7:TR?= MXexJIg> NWrQO|l[TE2VTx?= MVfk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= M3nHS|I1PDR5OUO1
H1975 NE\lSoFHfW6ldHnvckBCe3OjeR?= MnvwNVDDqM7:TR?= NHHVVoYyKGh? Mn;XSG1UVw>? MV;k[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= M2T3XVI1PDR5OUO1
MG-63 MmDPRZBweHSxc3nzJGF{e2G7 MnnTNVAhyrWP NHLQWlIyOiCq NGCzVXBmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MUGyOFM2QDNyMR?=
5637 NYjGRnN5SXCxcITvd4l{KEG|c3H5 MljzNVDDqM7:TR?= M4fz[lQxKG2rbh?= MY\y[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> MYqyOFM{Ozh4OB?=
HEK-293 M{K5fGZ2dmO2aX;uJGF{e2G7 NXTNS45tOTVybl2= NHXTdW4yPiCq NH3vWZJFVVOR M3G2SYRm[3KnYYPld{BEWlRiYXP0bZZqfHl? M{LKSFI1OzJ2M{[2
SW480  MUDGeY5kfGmxbjDBd5NigQ>? Mo\hNVUxdk1? NGe1fYwzOCCq MlvxSG1UVw>? M4rXTJJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NF3WZnUzPDN{NEO2Oi=>
HepG2 NVnDcGczTnWwY4Tpc44hSXO|YYm= NULS[pN4OTByIH7N MmH3NlQhcA>? NU\pWXlW[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NW[1N3d6OjR{OUe1NVA>
HCT 116  NYe5UpNSTnWwY4Tpc44hSXO|YYm= NUGxemszOTByIH7N MVqyOEBp NXK4UGNy[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NEDLR4UzPDJ7N{WxNC=>
BEL/FU NWfxSnRxTnWwY4Tpc44hSXO|YYm= M2DSelEhdU1? MUSyOEBp NFvWPIdl\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? NY\aVIdSOjR{M{KwPVk>
Huh7  NH;TSXZHfW6ldHnvckBCe3OjeR?= MXSzxsDPxE1? M3e4U|EhcA>? NXSzbnBPemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? MXWyOFE5PDF7Nh?=
A-375 NYXXU5NySXCxcITvd4l{KEG|c3H5 Mk\6OE85KM7:TR?= NFG0TFkzPCCq Mm[3[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MnHSNlQyOTNzN{O=
A-375-TS  M4XtWWFxd3C2b4Ppd{BCe3OjeR?= MoqwOE85KM7:TR?= MXeyOEBp NIXlUYZmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NV\Ge4QzOjRzMUOxO|M>
Mel-HO M37xbGFxd3C2b4Ppd{BCe3OjeR?= M4e4eFQwQCEQvF2= NXnqW4Z6OjRiaB?= MWHlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MojiNlQyOTNzN{O=
Mel-HO-TS MYnBdI9xfG:|aYOgRZN{[Xl? NHHmS401NzhizszN MVeyOEBp NYXzfHZY\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NFTLeHozPDFzM{G3Ny=>
MeWo NIe4[2xCeG:ydH;zbZMhSXO|YYm= NXWzUWE2PC96IN88US=> MlTUNlQhcA>? Mn;K[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MUeyOFEyOzF5Mx?=
Mel-2a MY\BdI9xfG:|aYOgRZN{[Xl? NFf4[oc1NzhizszN NVnRdVZqOjRiaB?= Mnrv[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NHHib2EzPDFzM{G3Ny=>
MDA-MB-231 MkPBSpVv[3Srb36gRZN{[Xl? MUiw5qCUPDByIH7N M4LKd|QhcA>? MoHqd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUKyNlkxPjJ3OR?=
MDA-MB-231 NEGw[4JHfW6ldHnvckBCe3OjeR?= M4LUW|QxOCCwTR?= NVPyOJZRPCCq M4HodoRm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4XtdFIzQTB4MkW5
Jurkat MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzONmQxNjJ3LUGuNlUh|ryP M16zdlI1NzR6IHi= M3fo[mROW09? NHL6VGpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MVmxPVc2PzF6NR?=
Namalwa NVXWV5hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HYTlAvOjVvMT6yOUDPxE1? NX7nbJlVOjRxNEigbC=> MVrEUXNQ NWDJdZVocW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M3HRTVE6PzV5MUi1
Jurkat NVPtdGh7SXCxcITvd4l{KEG|c3H5 M3\Xc|AvOjVvMT6yOUDPxE1? MnrLNlQwPDhiaB?= MlHGSG1UVw>? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MWOxPVc2PzF6NR?=
Namalwa MULBdI9xfG:|aYOgRZN{[Xl? NUX0d4VDOC5{NT2xMlI2KM7:TR?= NEnhSlMzPC92ODDo NHe3c3hFVVOR NUexd5BIcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M1jqWVE6PzV5MUi1
K562 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLWNlQhcA>? NF;NZYlKSzVyPUK1xtExNjF2IH7N NXHMdldGOTl4NkKzOlE>
SW1990 MWHGeY5kfGmxbjDBd5NigQ>? M3PERlAvODFvMTFOwG0> NHXVV5UyKGh? Ml;vbY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v MXixPVQ3QTB{MB?=
RT112  M4nzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNOKh|ryP NXjkeWJHOjRiaB?= MVTEUXNQ NYLGWJI{\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? M{HPWVE5Pzh5OEOy
MHG-U1 M1u2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNOKh|ryP MoDPNlQhcA>? MlLHSG1UVw>? NFrGXldl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? M4D5WlE5Pzh5OEOy
SMMC-7721 NVnyVGY5SXCxcITvd4l{KEG|c3H5 NXLFV3V{OjBywrDuUS=> M4XwN|I1KGh? Mnv4bY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? MljCNVc2PTdzOUG=
SMMC-7721 NWPEVVB4TnWwY4Tpc44hSXO|YYm= MlKxNlAxyqCwTR?= NVW2[ZBvOjRiaB?= M{fVVpVxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w NVXESGc5OTd3NUexPVE>
HeLa M2i5c2Z2dmO2aX;uJGF{e2G7 MoH4NVAxyqCwTdMg M3;hSVEhcA>? M4Dtd4FtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 MWKxOlg6ODlzNR?=
MRC5VI NWG0UnBlTnWwY4Tpc44hSXO|YYm= NF\xcVMyOi53IH3N NUm3fnk5OC53IHi= M{TYeGROW09? MoLJZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MXexOlIzPzN7NB?=
AT5BIVA M{e0N2Z2dmO2aX;uJGF{e2G7 MonmNVIvPSCvTR?= M1;yUVAvPSCq NGnOcZpFVVOR M{LKNYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NX\USZlYOTZ{MkezPVQ>
M059J M371V2Z2dmO2aX;uJGF{e2G7 MmrNNVIvPSCvTR?= Mo[0NE42KGh? MmLpSG1UVw>? MVnhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M2TFO|E3OjJ5M{m0
HeLa MUHGeY5kfGmxbjDBd5NigQ>? NUfOTm9UOTJwNTDtUS=> MY[wMlUhcA>? NWXVRnZFTE2VTx?= NXLnZo5v[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NF:2Xm0yPjJ{N{O5OC=>
N2a M3TGWmFxd3C2b4Ppd{BCe3OjeR?= NVTEZZZWOC5zLUGwJO69VQ>? MonXNkBp MYjpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NGi3NWYyPTh2Mke2Oy=>
Jurkat  MoLGT4lv[XOnIFHzd4F6 MlPuTWM2OCCxZjCyOEBvVQ>? MXyxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420
Smiles CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID